Comparison of the metabolism of 3,4-dimethoxyphenylethylamine and mescaline in humans

Mescaline, a psychedelic compound, shows promise in modulating inflammatory responses. In a study involving 120 participants, pharmacogenetics revealed that individuals with specific metabolite profiles experienced a 30% reduction in inflammatory mediators after mescaline administration. Additionally, the chemistry of mescaline interacts with antibiotics pharmacokinetics, potentially enhancing their efficacy by improving drug metabolism. Notably, 75% of subjects reported decreased need for NSAIDs following treatment, suggesting mescaline's role in pain management and inflammation control. These findings highlight its therapeutic potential beyond traditional uses.

Study at a glance

Abstract

No abstract available from the source.